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Abstract
Although androgen receptor (AR) function has been extensively studied, regulation of the AR gene itself has been much less
characterized. In this study, we observed a dramatic reduction in the expression of androgen receptor mRNA and protein in
hyperproliferative prostate epithelium of keratin 5 promoter driven E2F1 transgenic mice. To confirm an inhibitory function
for E2F1 on AR transcription, we showed that E2F1 inhibited the transcription of endogenous AR mRNA, subsequent AR
protein, and AR promoter activity in both human and mouse epithelial cells. E2F1 also inhibited androgen-stimulated
activation of two AR target gene promoters. To elucidate the molecular mechanism of E2F-mediated inhibition of AR, we
evaluated the effects of two functional E2F1 mutants on AR promoter activity and found that the transactivation domain
appears to mediate E2F1 repression of the AR promoter. Because DNMT1 is a functional intermediate of E2F1 we examined
DNMT1 function in AR repression. Repression of endogenous AR in normal human prostate epithelial cells was relieved by
DNMT1 shRNA knock down. DNMT1 was shown to be physically associated within the AR minimal promoter located 22 bps
from the transcription start site; however, methylation remained unchanged at the promoter regardless of DNMT1
expression. Taken together, our results suggest that DNMT1 operates either as a functional intermediary or in cooperation
with E2F1 inhibiting AR gene expression in a methylation independent manner.
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Introduction
Androgens are required for prostate gland development and for
prostatic function and glandular maintenance in the adult male
[1]. Androgen action is mediated through the androgen receptor
(AR), a ligand-activated nuclear transcription factor. AR expres-
sion is found in a variety of tissues, including prostate and breast,
and changes throughout development, aging and malignant
transformation (reviewed in [2]). AR exists in the cytoplasm and
is associated with at least three heat shock proteins, hsp56, hsp70
and hsp90 [3]. Upon androgen binding and activation of the AR,
heat shock proteins dissociate and expose a nuclear localization
domain which directs the receptor to the nucleus [4]. At the
nucleus, the androgen/AR complex undergoes dimerization and
phosphorylation prior to nuclear translocation and subsequent
binding to androgen response elements (ARE) in the promoter or
enhancer region of numerous androgen-responsive genes. Several
AR co-activators have been identified (ARA 70, ARA 55 and
ARA 54) which also interact with and regulate AR gene
transactivation [5,6]. Thus, ligand-activated AR may regulate
genes through a variety of mechanisms. AR function and the
signaling pathways regulated through androgen and AR interac-
tion have been extensively studied for decades; however,
regulation of the AR gene itself is not clearly understood.
Transcriptional regulation of AR is cell specific and age-
dependent [7,8]. The promoter region of the AR gene lacks
transcriptional regulatory sequences (TATA and CAAT), but is
rich in GC sequences [9,10]. There are at least two transcription
initiation start sites whose use vary depending on cell type [11].
Studies of the AR promoter have identified potential binding sites
for several transcription factors, however, there have only been a
few well characterized studies demonstrating transcriptional
regulation of AR. For example, Sp1 [9,11] has been shown to
be a positive regulator of AR gene expression, whereas, NF-kB
p50/p50 and NF-1 have been shown to be strong negative
regulators of AR [12,13]. The mechanisms underlying the
repression of the AR gene remain to be elucidated.
The E2F family of transcription factors control cell proliferation
by regulating cell cycle progression [14,15,16]. The E2F family has
eight characterized family members (E2F1-E2F8) which can form
heterodimers with DP family members (DP1, 2, and 3), giving rise
to functional E2F activity [16]. E2Fs control entry into the cell
cycle and regulate G1/S phase transition by regulating the
transcription of genes that encode cell cycle regulatory proteins
including Cyclin E, Cyclin A, Cdc 2, Cdc 25A, and proliferating
nuclear cell antigen (PCNA), as well as enzymes involved in
nucleotide biosynthesis such as dihydrofolate reductase, thymidyl-
ate synthase and thymidine kinase [17]. E2F1, E2F2 and E2F3 are
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responsive genes, whereas E2F4, E2F5, E2F6, E2F7, and E2F8
act as transcriptional repressors. Overexpression of E2Fs 1–3 in
serum starved cells induces S-phase entry and DNA synthesis by
binding to DNA response elements and activating the transcrip-
tion of E2F target genes [17,18,19]. E2Fs 1–3 can also override
growth-arrest signals induced by Cdk inhibitors p16 [19] and can
act as both oncogenes and tumor suppressors [20,21,22]. E2F1
binding sites have been reported in the promoters of the breast
cancer susceptibility gene BRCA1 [23], p73 [24,25], the tumor
suppressor gene p14
ARF [26], and the gene for apoptosis protease-
activating factor 1 (Apaf-1) [27]. We have identified E2F binding
sites in the promoter of DNA methyltransferase 1 (DNMT1) that
allow for regulation by E2F1 [28]. E2F1 has also been shown to
act as a direct transcriptional repressor for several genes including
urokinase-type PA (uPA) [29], the anti-apoptotic protein Mcl-1
[30], and human telomerase reverse transcriptase [31]. These
results suggest that E2F1 can have both positive and negative
regulatory roles on gene transcription, however the molecular
basis of these disparate functions is not known.
The DNA methyltransferases (DNMT 1, 3a, 3b and 3L) play an
integral role in the epigenetic regulation of many genes. All
DNMTs except for 3L have a catalytic domain that facilitates the
transfer of methyl groups from S-adenosyl-methionine to cytosines
located in CG dinucleotides. DNMT 3a and 3b are generally
responsible for genome-wide de novo methylation during early
embryogenesis [32]. DNMT3a is shown to methylate both
maternally and paternally imprinted genes in germ-line cells
[33], while DNMT3b maintains the chromosomal stability of 6, 9,
and 16 via centromeric methylation [34]. Genomic methylation by
DNMT3 (a and b) is enhanced in the presence of DNMT3L [35].
Initial methylation by the DNMT3 family members is maintained
by DNMT1, which has an affinity for hemi-methylated DNA
during replication and cell division. DNMT1 is necessary for
mouse fetal development and the progenitor and self-renewing
characteristics of somatic cells located in the epidermis [36]. As
mentioned, DNMT1 was characterized in our lab to be a direct
transcriptional target of E2F1 [28] and may mediate targeted
repression by E2F1.
In this study, we explored a regulatory mechanism that controls
the endogenous expression of AR in prostate epithelium. We
investigated the effects of the transcription factor E2F1 on AR
mRNA and protein expression in both human and mouse prostate
epithelial cells. We demonstrate how E2F-1, a classical transcrip-
tional activator, might cooperate with DNMT1 to repress AR
transcription in the prostate gland.
Results
Transgenic K5-E2F1 prostate glands exhibit hyper-
proliferative epithelium and an atypical morphology
Accumulating evidence suggests that increased E2F1 activity
reactivates several aspects of benign and malignant disease
including increases in cellular proliferation [37,38]. We have
shown previously that normal human prostate gland expresses low
levels of E2F1 [39]. We observed that keratin 5 promoter driven
expression of the human E2F1 gene in the mouse prostate gland
[40], resulted in hyperproliferative changes that were not detected
in wild type mice (Figure 1A). This K5 promoter fragment is
known to direct transgene expression to the basal cell compart-
ment of stratified epithelia of several glandular tissues such a
mammary gland, salivary gland and prostate [40,41]. In K5-E2F1
transgenic mice, the majority of glands appeared grossly normal
and were lined with a single layer of epithelial cells, however there
were focal areas of increased epithelial hyperplasia with abnormal
gland architecture in the dorsolateral lobe of the prostate
(Figure 1A). Some glands had increased stratification of epithelial
cells that formed compact glands with a cribriform growth pattern,
representative of prostatic intraepithelial neoplasia (PIN) and some
nuclear atypia. Similar lesions were not detected in wild type
animals. Prostate tissue from age and strain-matched wild type
mice consisted of normal prostatic ducts lined with a single layer of
epithelial cells surrounded by a thin layer of stroma (Figure 1A).
To further define a role for E2F1 in prostate epithelial cell growth,
we generated prostate epithelial cells lines from glands harvested
from two wild type mice and three K5-E2F1 transgenic mice.
Semi-quantitative RT-PCR analysis using specific primers for
mouse and human E2F1 show the presence of endogenous mouse
E2F1 in wild type and K5-E2F1 cells, however, human E2F1 was
only detected in K5-E2F1 cell lines (data not shown). In agreement
with the hyper-proliferative epithelial histology, the K5-E2F1 lines
exhibited a 2 fold increase in cell viability compared to wild type
Figure 1. E2F1 leads to atypical prostatic morphology and
increases prostate epithelial proliferation in a K5-E2F1 trans-
genic mouse. (A) Histology of prostate tissue taken from both K5-E2F1
transgenic and wild type mice. (B) Prostate epithelial cell lines
established from both transgenic and wild type mice were analyzed
by western blot for the expression of E2F1, cell cycle genes (Cyclin E and
PCNA), the epithelial cell specific marker E-cadherin (E-cad), and
Androgen Receptor (AR). Actin is shown as a loading control. (C) A
trypan blue exclusion assay was implemented to measure the viability
of cell lines obtained from the mouse models. Each point represents the
mean of three independent experiments with the standard deviation.
doi:10.1371/journal.pone.0025187.g001
Repression of Androgen Receptor Expression
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25187cells (Figure 1C). We also observed a significant reduction of K5-
E2F1 cells in G1 phase and a concurrent increase in the
distribution of cells in G2/M and S phase (data not shown).
Western blot analysis reflected E2F1 expression and revealed a
significant increase in human E2F1 protein expression in all three
K5-E2F1 transgenic lines compared to wild type controls
(Figure 1B). To investigate the molecular events associated with
increased E2F1 expression, we analyzed several regulators of
prostate epithelium in addition to E2F1 target genes. Whole cell
lysates prepared from log phase wild type and K5-E2F1 cells were
analyzed for Cyclin E and PCNA protein levels. K5-E2F1 cells
exhibited an approximate 3 fold increase in Cyclin E and a 2 fold
increase in PCNA (Figure 1B). Cyclin E and PCNA are E2F1
target genes that regulate DNA synthesis and promote G1/S
transition, suggesting that E2F can control both DNA replication
and mitotic activities in our transgenic prostate model and cell
lines [42,43]. The prostate epithelial lineage of these cell lines was
verified by the expression of the epithelial cell marker E-cadherin
(Figure 1B) and the steroid hormone receptors estrogen receptor-
beta (ER-b) (data not shown). All 3 K5-E2F1 lines exhibited
significant repression of AR protein compared to the wild type
cells (Figure 1B).
E2F1 down regulates AR expression and the promoter
activity of AR target genes
To determine if E2F1 directly represses AR transcription, we
examined whether exogenous expression of E2F1 reduces AR
mRNA levels in prostate epithelial cells. Stable E2F1 over-
expressing clones were established in mouse prostate epithelial cells
(PrE) and two clones, PrE2F1-1 and PrE2F1-2, were expanded and
characterized. Total RNA was harvested and subjected to Northern
blot analysis for the detection of AR and E2F1 mRNA. Both clones
exhibited increased E2F1 mRNA and significantly reduced AR
mRNA (Figure 2A) and protein (Figure 2B). These cells exhibited
increased E2F activity by exhibiting increased expression of Cyclin
E and PCNA; two well described E2F-target genes (Figure 2B).
These result demonstrated that exogenous E2F1 is involved in the
repression of AR expression.
The findings from the transgenic animals indicated that E2F1
might be driving a proliferative and undifferentiated phenotype.
We had previously observed the AR-regulated prostate specific
antigen (PSA) gene was down regulated following E2F1 over
expression suggesting a repressive activity of E2F1 on AR target
genes through the repression of AR [39]. To explore this
possibility, we examined the effect of E2F1 on a hormone-
responsive promoter/reporter construct (3XHRE-Luc) in the
androgen-responsive prostate cell line, LNCaP. The 3XHRE-
Luc construct has 3 hormone response elements cloned in front of
a luciferase reporter gene and allows for the monitoring of directed
hormone receptor activation. LNCaP cells were co-transfected
with the 3XHRE-Luc construct with either pcDNA3 (empty
vector) or E2F1. We treated cells with the synthetic androgen
R1881 to specifically activate AR and observed activity from the
3XHRE-Luc reporter (Figure 2C). Co-transfection of E2F1 both
abrogated 3XHRE-Luc activity in the presence of R1881 and
down regulated AR protein expression (Figure 2C). These results
demonstrate that E2F1 inhibits transcriptional regulation of AR
target gene promoters by inhibiting AR expression.
Transcriptional repression of AR requires the
transcriptional regulatory domain of E2F1
To determine if E2F1 exerts repressive activity directly on the
AR promoter, we utilized a 1.5 kb (21571 to +131 bp) mouse AR
promoter construct (Figure 3A) cloned upstream of a luciferase
reporter cassette (mAR-Luc). This plasmid was co-transfected into
normal mouse prostate epithelial (mPrE) cells with either empty
pcDNA3 vector (control) or wild type E2F1 along with a CMV
promoter-driven b-galactosidase (B-gal) reporter plasmid as an
internal control. Wild type E2F1 reduced mouse AR promoter
activity 3.5 fold compared to cells transfected with empty
pCDNA3 plasmid (Figure 3A). To assess AR promoter activity
resulting from the direct disruption of E2F1 activity, we used a
dominant negative E2F1 (DN E2F1) construct encoding a fusion
cassette of the E2F1 DNA binding and the Rb pocket domain.
Figure 2. Exogenous E2F1 inhibits both AR expression and
responsive promoters. (A) Northern blot analysis of stably transfect-
ed mouse prostate epithelial cells (PrE) with either pCDNA3 (control
vector) or E2F1 shown as E2F1-1 and E2F1-2 to detect AR and E2F1
gene transcription. The 28S and 18S ribosomal bands are shown for
loading comparison. (B) Western blot analysis of whole cell lysates
harvested from PrE cells stably transfected with pcDNA3 (control) or
E2F1 for the detection of AR, Cyclin E, and PCNA. b-actin is shown as a
loading control. (Aa n dB )The northern blot and western is
representative of 3 separate experiments. LNCaP cells were co-
transfected with 1 mg of ARE-Luc (C) and 500 ng of either empty
pcDNA3 vector or E2F1 in the presence of 10
29 M R1881. Results were
normalized to b-galactosidase (B-gal) from a co-transfected CMV
promoter driven B-gal reporter construct. The histogram represents
the mean value of three independent experiments with the indicated
standard deviation. The western depicts the expression levels for E2F1
and AR relative to tubulin for the transfection and treatment conditions.
* indicates P,0.05 for the indicated comparison in brackets.
doi:10.1371/journal.pone.0025187.g002
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E2F1 activity at E2F1-responsive promoters [44] and when
employed in our system relieved repression of the AR promoter.
As a control, we demonstrated that E2F1 activates an E2F-
inducible promoter containing 4 adjacent E2F consensus binding
sites (E2F-Luc), while the DN E2F1 construct repressed promoter
activity. We also demonstrated that E2F1 does not have an effect
on an unrelated CRE-Luc promoter, which contains 4 adjacent
cyclic AMP regulatory elements in front of a luciferase reporter
construct. We demonstrated that exogenous E2F1 repressed AR
Figure 3. The E2F1 transactivation domain is required for AR promoter activity repression. (A) mPrE cells were co-transfected with 1 mg
of mARp-Luc, E2F-Luc or CRE-Luc luciferase reporter constructs with 0.5 mg of empty vector (pcDNA3), wild type E2F1, dominant negative E2F1 (DN
E2F1) or SV-40 Large T antigen (Tag). After 72 hours, cells were harvested and assayed for luciferase expression. The results are shown as averages of
three independent experiments. Assays were done in triplicate and mean values are shown with standard deviation. The results were normalized to
b-galactosidase (B-gal) expression from a co-transfected CMV promoter driven B-gal reporter construct. (B) LNCaP cells were co-transfected with
either 1 mg of hAR-Luc or DHFR-Luc and 0.5 mg of either wild type E2F1or E2F11–284 mutant constructs. The histograms represent the mean value of
three independent experiments with the indicated standard deviation. Results were normalized to b-galactosidase (B-gal) expression from a co-
transfected CMV promoter driven by a B-gal reporter construct. * indicates P,0.05 for the indicated comparison in brackets.
doi:10.1371/journal.pone.0025187.g003
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this repressive activity, we disrupted the inhibitory effect of
endogenous Rb on E2F1 by co-transfection with SV-40 large T
antigen (Tag) and assessed AR promoter activity. Ectopic
expression of Tag led to 9 fold activation of the E2F-Luc
promoter, but repressed mAR promoter activity nearly 4 fold
(Figure 3A). These results confirm that E2F1, normally a
transcriptional activator, participates in the repression of the AR
promoter.
To elucidate the mechanism of E2F-mediated inhibition of AR,
we examined the effects of two functional E2F1 mutants on AR
promoter activity. A mutation in the DNA binding domain (Eco
132) failed to significantly relieve E2F-mediated inhibition
(Figure 3B). However, deletion of the transactivation domain of
E2F1 (E2F11–284) abrogated the inhibitory effect of E2F1 on the
AR promoter (Figure 3B). As expected, these E2F1 mutants did
not activate the dihydrofolate reductase-luciferase reporter
construct (DHFR-Luc), which is known to require both E2F1
transactivation and DNA binding domains (Figure 3B). These
results indicate that the transactivation domain of E2F1 appears to
be more essential than the DNA binding domain for E2F1
repression of the AR promoter. This observation prompted us to
examine co-repressive factors that are involved in the E2F1
mediated repression of AR.
DNMT1 down regulation relieves AR repression in AR
negative cells lines
We have previously shown that the DNA methyltransferase 1
(DNMT1) gene, which typically functions to maintain the
methylation and repression of specific genes, was trans-activated
by E2F1 [28]. Interestingly, DNMT1 may also exist in a repressive
complex that includes E2F1 [45]. To determine if DNMT1 is
involved in E2F1 dependent repression of AR transcription, we
assessed whether AR expression is relieved in the AR negative
defined human primary prostate epithelial cells (hPrEC) following
DNMT1 shRNA knockdown. The hPrEC line is a model of
transit/amplifying cells of the prostate gland and as such lacks
markers of terminal differentiation such as AR expression [46,47].
These cells allow for the study of normal mechanisms that regulate
AR expression. The hPrEC line was subjected to a transient
transduction with either empty short hairpin RNA (shRNA),
vector, non-targeting shRNA or DNMT1 targeting shRNA (4-1
and 4-2) (Figure 4A) and processed for both qRTPCR and western
blot analysis. Compared to controls the expression of the DNMT1
shRNA sequence resulted in a significant decrease in DNMT1
expression at both the transcriptional (data not shown) and protein
level (Figure 4A). AR protein and transcription increased in
response to decreases in DNMT1 expression, indicating that gene
repression may also involve DNMT1. To assess the role of
DNMT1 on AR promoter activity, we cloned a region of the AR
gene containing a 2 kb human AR promoter upstream of a
luciferase reporter (hAR-Luc). Because primary hPrEC cells
cannot withstand multiple passages required for stable shRNA
transduction, we employed the immortalized human prostate
epithelial line, BPH1, which still maintain a non-transformed
phenotype [48]. The hAR-Luc construct along with a CMV
promoter-driven b-galactosidase internal control reporter were co-
transfected into BPH-1 cells that were previously transduced with
DNMT1 shRNA targeting constructs (Figure 4B). DNMT1
shRNA relieved AR promoter activity in BPH-1 cells when
compared to controls (Figure 4C). These results suggest that
DNMT1 contributes to the repression of AR promoter activity in
normal prostate epithelial cells.
DNMT1 associates with the intronic and minimal
promoter regions of the AR gene independent of
methylation activity
To understand how DNMT1 functions to represses AR
expression, we explored the possibility for DNMT1 to physically
associates with the AR gene. Chromatin immunoprecipitation
sequencing (ChIP-seq) analysis identified both DNMT1 and E2F1
associated regions across the whole hPrEC genome (data not
shown). H-peak analysis [49,50] of the data revealed regions in the
AR genomic structure exhibiting significant DNMT1 and E2F1
co-occupancy. Considering that DNMT1 has been reported to
form complexes that bind to E2F responsive promoters, we
designed primers flanking specific E2F consensus sequences (site A,
B, and C) in the AR promoter. Site A and B were located within
1,000 bps of the transcription start site, while site C corresponded
to a location in the ChIP-seq identified region of DNMT1 and
E2F1 co-occupancy in the first intron (Figure 5A). Although the
ChIP-seq demonstrated some E2F1 associations with the AR gene,
we focused our ChIP analysis on DNMT1 interactions, consid-
ering that the region under analysis presented with weak E2F
consensus sites and that the E2F1 DNA binding domain was not
necessary for AR promoter repression (Figure 3B). Primers were
used to analyze a known binding target of DNMT1 located in the
PS2 promoter [51] and a non-related DNA sequence located in
exon 2 of the ABCB1 gene [52]. Rabbit IgG was used to control
for any non-specific DNA binding incurred by the antibodies.
Quantitative PCR indicates that DNMT1 strongly associates with
intronic region showing a $4-fold over non-specific enrichment at
the ABCB1 genomic region. DNMT1 demonstrated some
association with sites A and B in the AR gene, showing slightly
increased levels of enrichment over ABCB1, that were similar to
amplification levels at the PS2 promoter (Figure 5B). DNMT1,
therefore, associates with the 59 UTR and a region in the first
intron of the AR gene that has a possible affinity for E2F1.
DNMT1 is traditionally thought to facilitate the repression of
target genes through a catalytic process that involves the transfer of
methyl groups to cytosines located in CG dinucleotides present in
the DNA sequence. Aberrant hyper-methylation of the AR
promoter has been detected in the AR negative metastatic prostate
cancer cell lines DU-145 and TSU-PR1 [53]. ChIP analysis
demonstrated that DNMT1 associated with a section of DNA
spanning a region (+44 to +54) of heavy methylation conserved
between DU145s and other transformed AR lacking cell lines [54].
To determine whether methylation of the AR minimal promoter
associated region (Figure 5A) is dependent on DNMT1, we
sequenced a section (+22–+293) of bisulfite converted DNA
extracted from DU145s and hPrECs infected with DNMT1
shRNA. The methylation pattern remained unchanged in the
absence of DNMT1 when compared to the cells infected with the
non-targeting shRNA construct (NT) in DU145s, while subtle
increases were observed in a single hPrEC DNMT1 knockdown
cell line (Figure 5C). According to this data, methylation at the AR
minimal promoter appears to mostly occur in a DNMT1
independent fashion. We additionally demonstrated that AR
expression resulting from the down regulation of DNMT1
occurred regardless of methylation at the bisulfite sequenced
region (+22–+293) in hPrECs. To further asses the possibility for a
methylation independent process we treated both DU145 and
hPrEC lines with a global DNA methylation inhibitor, 5-aza-29-
deoxycytidine (5-Aza) and observed no change in AR transcription
(Figure 5C). These data point to a possible mechanism of AR
repression in normal prostate epithelial cell lines that utilizes
methylation - independent DNMT1 activity.
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In this study we have shown that E2F1 either drives the
expression of or cooperates with DNMT1 to repress AR
transcription in normal undifferentiated prostate epithelium.
Specifically, exogenous E2F1 down-regulated AR promoter
activity and mRNA and protein expression, while a dominant
negative E2F1 construct (DN-E2F1) relieved AR promoter
repression by inhibiting access of endogenous E2F1 to E2F
targeted promoters. All of these observations correlated with
variations in activation of the E2F-target gene promoter DHFR-
Luc, and changes in expression levels of endogenous cell cycle
regulatory proteins consistent with E2F1 activity. The use of E2F1
functional mutants suggests that the transcriptional regulatory
domain of E2F1 comprises this repressive activity possibly through
the interaction of an intermediary co-repressor. Based on studies
showing that DNMT1 is both a target [28] of E2F1 and that it
may co-repress some targets with E2F1 [45], we decided to
evaluate the role of DNMT1 in AR repression. Targeted
knockdown of DNMT1 relieved AR promoter activity, mRNA
and protein expression. Additionally, DNMT1 directed ChIP
showed association of DNMT1 with the AR promoter. The lack of
de novo methylation at the minimal AR promoter following loss of
DNMT1 suggests DNMT1 represses AR expression in a
methylation independent manner.
Sharma et al. have recently demonstrated that E2F1 transacti-
vates the AR gene on a depleted RB1 background in an
engineered model of castrate resistant prostate cancer [55]. This
observation is interesting in light of our findings in non-
transformed prostate epithelium in which E2F1 represses AR
transcription in the presence of functional pocket proteins. Our
findings that the Large T antigen facilitates E2F1-mediated
repression of AR, suggests that E2F1 has roles in both the
activation and repression of AR transcription. While Sharma et al.
provide evidence for a mechanism of AR activation that involves
the association of E2F1 with specific regions of the AR promoter;
our results did not find association of E2F1 with these reported
sites, but revealed regions exhibiting weak E2F1 consensus binding
downstream of the AR transcription start site that demonstrated
DNMT1 association instead. The only common site studied
Figure 4. DNMT1 downregulation relieves AR Expression. (A) Primary cultures of human prostate epithelial cells (hPrEC) and (B) immortalized
benign prostate epithelial cells (BPH-1) transduced with either control (shVector (shV) and shNon-targeting (NT)) or DNMT1 shRNA constructs. AR and
DNMT1 protein expression relative to actin loading control were analyzed by Western blot. The exposures in (B) were taken from different sections of
the same blot at the same intensity. AR transcription was analyzed using qRTPCR with readings done in triplicate (graphs A and B). Mean values are
represented with standard error bars. (C) shRNA transduced BPH-1 cells (described in A and B) were transfected with the human AR promoter
luciferase reporter (hAR-Luc) construct. The histograms represent the mean value of three independent experiments with the indicated standard
deviation. Results were normalized to b-galactosidase (B-gal) expression from a co-transfected CMV promoter driven B-gal reporter construct. All
western blots are representative of 3 separate experimental replicates.
doi:10.1371/journal.pone.0025187.g004
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with no AR activation, but moderate DNMT1 binding associated
with AR inhibition. These seemingly contradictory findings might
begin to explain how E2F1 functions in a more traditional role to
activate AR in the absence of RB in prostate cancer cells, yet
represses AR transcription in normal (non-transformed and non-
immortalized) prostate epithelium in the context of functional RB.
Although E2F1 is thought to primarily function as a positive
regulator of transcription, a negative regulatory role of E2F1 has
also been described for a number of genes [29]. Unlike its positive
regulatory function, which is mediated by the direct interaction of
E2F1 with DNA, the mechanism(s) for E2F1-mediated negative
regulation are still largely unknown. Crowe et. al. identified two
putative E2F binding sites in the hTERT promoter that were
important for E2F1- mediated repression [31]. The E2F1 mutant
(E132) which lacks the DNA binding domain of E2F1 was
inefficient at repressing hTERT promoter activity, suggesting that
the DNA binding domain was essential for repression. In another
study, direct repression of the Mcl-1 promoter by E2F1 also
required the DNA binding domain, but not the transactivation
domain [30]. Koziczak et. al. demonstrated that both the DNA
and transactivation binding domains of E2F1 were necessary for
the negative regulation of uPA and the PA inhibitor (PAI-1) genes
[29] however, E2F repressed promoter activity independently of
the pocket protein Rb. We have shown here that E2F1-mediated
repression independent of Rb pocket protein family members,
suggesting that multiple mechanism(s) exist for E2F1-mediated
repression. We noted that the AR promoter does not contain a
strong E2F1 consensus binding site (TTTGCGG/CG/CAAA),
furthermore the E2F1 DNA binding domain was not required for
repression of the AR promoter suggesting that E2F1 does not bind
directly to the AR promoter, but cooperates with other regulatory
proteins to repress AR. Our data demonstrate that the carboxy-
terminal transactivation domain was essential for E2F1 suppres-
sion of the AR promoter (Figure 3) and therefore supports two
possible models of AR repression. Several proteins are known to
bind to this region and regulate transcription including CREB-
binding protein [56], MDM2 [57] and TRRAP/Tip60 complex
Figure 5. Methylation independent association of DNMT1 with the AR gene. (A) Map of a region of the AR promoter depicting two types of
E2F consensus sequences +80R+96 and +13,318R+13,334 (shown as solid ovals) and +999R+1,015 (shown as open ovals). Primer flanked regions
are designated as sites A, B, and C. The 243 bp region (+22R+293) analyzed by bisulfite sequencing is indicated. (B) qPCR analysis of target (DNMT1)
and non-specific (IgG) ChIPed DNA from BPH-1 cells using primers that flank sites A, B, and C. Primers flanking a region in the PS2 (targeted DNMT1)
promoter and ABCB1 (non-targeted DNMT1) region were used as ChIP controls. Data is representative of the mean from 3 qPCR reactions and shown
as a percent of input with the standard error indicated. (C) Bisulfite sequencing analysis of the 243 bp region in the AR minimal promoter in hPrEC
compared to DU145 cells infected with both non-targeting (NT) (control) and DNMT1 shRNA constructs (4-1 and 4-2). Solid circles (methylated) and
open circles (un-methylated) were used to represent the methylation status of cytosines within CpG dinucleotides. Each horizontal strand of circles
depicts a separate DNA clone. Lysates were probed on a western blot for AR and actin. Cell lines were also treated with either 1 mM 5Aza (5A) or
DMSO matched vehicle (V) and extracted cDNA was PCR amplified with both human AR and GAPDH. All data shown except for the 5Aza treatments
are representative of 3 separate experimental replicates.
doi:10.1371/journal.pone.0025187.g005
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known repressive complex that includes Rb, HDAC1, and
DNMT1 through an as of yet undefined domain. The transactiva-
tion domain also interacts with the basal transcription factor IIH
(TFIIH) [59] which may facilitate the E2F1 contacts necessary to
induce transcription at the DNMT1 promoter, increasing
DNMT1/AR gene interactions that lead to repression (Figure 6).
Our findings along with previous work in the lab support a linear
model of AR repression that is reliant on the positive transcription
of DNMT1 by E2F1, however, the possibility remains for E2F1 to
regulate AR expression through a complex involving DNMT1
(Figure 6).
We have shown through targeted knockdown of DNMT1 and
ChIP analysis that the association of DNMT1 with weak E2F
consensus sites in the AR gene inhibits transcription. A previous
study has shown that estrogen receptor (ER) re-expression at both
the transcriptional and protein level, results from the targeted
inhibition of DNMT1 in ER negative breast cells [60]. DNMT1 is
traditionally thought to cause genetic repression through methyl-
ation; however, the current understanding of methylation
facilitated repression continues to evolve in the field of epigenetics.
Glypican 3 (GCP3), a developmental associated gene, is regulated
by a promoter methylation independent mechanism in human
fetal systems [61]. Methylation sensitive restriction digests show
that methylation at the GPC3 promoter is sex specific and occurs
regardless of GPC3 expression status in females, but remains
absent in males. Yakabe et. al. demonstrated through ChIP
analysis that methyl CpG binding protein 2 (MeCP2), which is
usually dependent on DNA methylation for genetic interaction,
was able to both associate with unmethylated promoter sequences
and regulate the expression of a subset of selected genes [62].
Furthermore DNMT1 was reported to repress p21 and BIK in a
methylation independent manner [63]. Epigenetic regulation
possibly involves the intercommunication of multiple epigenetic
marks to orchestrate the regulation of genetic expression. The
simultaneous employment of ChIP and methyl specific primer
(MSP) analysis, verified the presence of transcription promoting
histone modifications (acetyl-H3K9 and dimethyl-H3K4), associ-
ated with unmethylated regions responsible for facilitating hTERT
expression from a heavily methylated promoter in cancer cells
[64]. The role of methylation independent DNMT1 regulation at
the AR promoter may involve other epigenetic modifications.
DNMT1 appears to function in concert with other factors to
regulate gene expression. Heterochromatin protein 1 (HP1) GST
fusions pull down DNMT1, 3a, and 3b [65]. Smallwood et. al. and
colleagues further demonstrated that methylation by DNMT1 in
complex with the HP1 proteins was dependent on G9a H3K9me2
using in vitro chromatin array methylation assays. DNMT1 is also
known to directly interact with the enhancer of zeste 2 (EZH2)
protein, which mediates H3K27me2/3, in the context of the
Polycomb repressive complexes (PRC2/3) [66]. Furthermore,
DNMT1 was shown to associate with histone deacetylase activity
during direct interaction with HDAC1 [67] and in complex with
HDAC2 and corepressor DMAP1 [68]. DNMT1 is likely to
facilitate repression at the AR promoter through the interaction
with a multi-subunit complex.
Clearly, mechanisms for AR amplification and mutation play a
role in prostate cancer progression, however, loss of AR has been
reported in a subset of hormone-independent cancers, including a
complete loss in some cases [69,70]. Highly proliferative cells that
present with an AR negative phenotype are actually necessary for
normal prostate development. Prostate stem cells differentiate into
an AR negative transit-amplifying (TA) population that is known
to transiently undergo multiple rounds of cellular division before
terminally differentiating into AR positive luminal epithelium [47].
Certain prostate cancers may present with mutations that allow for
unhindered TA cell proliferation as mentioned in a review by Paul
C. Marker [71]. Our findings demonstrate that exogenous E2F1
Figure 6. Schematic representation of AR repression through the E2F1/DNMT1 axis. The use of either a dominant negative E2F1 construct
or a shRNA to knock down DNMT1 both result in the downregulation of DNMT1 and subsequent rescue of AR expression. E2F1 overexpression
experiments suggest that elevated E2F1 levels increase DNMT1 protein expression that associates directly with the AR promoter or possibly in
complex with E2F1 to repress AR.
doi:10.1371/journal.pone.0025187.g006
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3XHRE-Luc in a minimally invasive cell line, and that the
repression is possibly mediated by methylation independent
DNMT1 activity at the AR promoter in TA cells.
We suggest that the repression of AR may facilitate a
proliferative state in normal transit amplifying basal cells.
However, androgens are generally understood to promote
epithelial proliferation in AR–responsive cell lines, such as LNCaP
and in the regenerating prostate gland following castration. Some
suggest that androgens may contribute to re-expanding cellular
populations by directly activating androgen receptors expressed in
the epithelium. While studies demonstrate that the proliferation of
the developing epithelium is supported by the secretion of growth
factors from AR activated stromal cells [72], Waltregny et. al.
observed proliferation in a population of AR positive luminal
epithelial cells during androgen induced prostate regeneration
[73]. However, the authors demonstrated that luminal cells
additionally expressing p27 failed to proliferate in the epithelium.
AR activation by androgens is also thought to drive an anti-
proliferative program in the in prostate epithelium as well.
Directed expression of functional AR in both malignant and
non-transformed AR negative human cell lines (PC-3 and BPH-1)
reduced proliferation following androgen stimulation [74,75].
Tam et. al. demonstrated that the anti-proliferative effect of
melatonin on minimally transformed prostate epithelial cells
requires the transcriptional upregulation of p27kip1 by AR [76].
The lack of AR expression in prostate epithelial cells may therefore
be associated with proliferation as knockout of AR in mouse
prostate epithelium resulted in epithelial hyper-proliferation [77].
Mechanisms of AR repression may contribute to epithelial
proliferation and although the role of E2F1 in regulating prostate
epithelial growth is still not fully understood, we propose that the
inhibition of AR expression by the E2F1/DNMT1 axis may be
required for normal growth of specific basal cell population in the
prostate gland.
Materials and Methods
Cell Culture
LNCaP and DU145 cell lines obtained from American Type
Culture Collection, Rockville, MD and BPH-1 cells received from
Dr. Simon Hayward, Vanderbilt University Medical Center [48]
were cultured in RPMI 1640 medium supplemented with 8% fetal
bovine serum (FBS), 0.1% penicillin/streptomycin and 0.1% L-
glutamine. Human prostate epithelial cells (hPrEC) purchased
from Lonza/Clonetics, Walkersville, MD were maintained in
Prostate Epithelial Cell Growth Medium (Lonza/Clonetics).
Mouse prostate epithelial (PrE) cells, previously described in
reference [78] were cultured in RPMI 1640 medium supplement-
ed with 5% fetal bovine serum (FBS), 0.1% penicillin/streptomy-
cin and 0.1% L-glutamine.
For the development of the PrE-E2F1 stable cell lines, PrE cells
were transfected with pcDNA3-E2F1 (kindly provided by W.
Kaelin [79], or empty vector pcDNA3 (Invitrogen, Carlsbad, CA)
using Tfx50 (Promega, Madison, WI) according to the manufac-
turer’s protocol. Stable clones were selected in RPMI 1640 media
containing 5% FBS, 0.1% penicillin/streptomycin, 0.1% L-
glutamine and 200 m/ml G418 (Sigma, St. Louis, MO). For the
development of the DNMT1 knock-down stable BPH-1 and
transient hPrEC cell lines, cells were lentivirally infected with a
pLKO.1-puro vector either expressing DNMT1 specific short
hairpin RNA (shRNA) (clone ID: NM_001379.1-1687s1c1), non-
targeting shRNA (Cat#: SHC002) or no shRNA insert (Sigma/
Mission, St. Louis, MO). Stable shRNA BPH-1 clones were
selected in RPMI 1640 media containing 8% FBS, 0.1%
penicillin/streptomycin, 0.1% L-glutamine and 1 mg/ml puromy-
cin (Sigma, St. Louis, MO).
Cell treatments
All synthentic androgen (R1881) treatments were done at
10
29 M for 24 h after 15 h of serum starvation. All 5-aza-29-
deoxycytidine (5Aza) (Sigma) treatments were done in either
complete culturing media used for DU145 or hPrEc lines. Fresh
media containing 1 mM 5Aza was added every 24 h for a total of
72 h and DMSO treatments were matched as vehicle controls.
Northern Blot Analysis
Total RNA was prepared using QIAGEN RNA Easy kit per
manufacturer’s protocol (QIAGEN, Valencia, CA). Twenty
micrograms of RNA was resolved by gel electrophoresis under
denaturing conditions and RNA was transferred to a Duralon-UV
membrane (STRATAGENE, La Jolla, CA) overnight by capillary
action in 206SSC buffer (3 M NaCl and 0.3 M Na Citrate). RNA
was crosslinked to the membrane by UV cross linking. A 1.6 kb
human AR cDNA fragment was isolated from CMV3-hAR3.1
(kindly provided by D. Robins, University of Michigan, Ann
Arbor, MI) using a HindIII and NheI restriction enzyme sites. A
1.5 mouse AR cDNA fragment was isolated from CMV5-mAR
(kindly provided by D. Robins, University of Michigan, Ann
Arbor, MI) using HindIII restriction enzyme sites. The human and
mouse AR cDNA fragments were gel purified using QIAGEN Gel
Purification Kit, per manufacturer’s protocol and subsequently
labeled with [a-
32P] dATP using the random oligonucleotide-
primer labeling kit (STRATAGENE) and purified on STRA-
TAGNE Nucleotide Push Columns following manufacturer’s
protocol. The [a-
32P] dATP labeled probes were hybridized to a
Duralon-UV membrane (STRATAGENE) at 65uC overnight in
hybridization buffer (0.25 M Na2HPO4, pH 7.2 and 7% SDS)
while rotating. The membrane was subsequently washed twice for
45 min each in 20 mM Na2HPO4, pH 7.2 and 5% SDS followed
by two additional washes for 45 min each in 20 mM Na2HPO4,
pH 7.2 and 1% SDS. The membranes were exposed to X-ray
film (Kodak, Rochester, NY) overnight and visualized by
autoradiography.
Western Blot Analysis
Cells were either trypsinized, centrifuged and washed one time
with PBS then lysed with RIPA buffer (50 mM Tris pH 8.0,
120 mM NaCl, 0.5% Nonidet P40, 1.0 mM EGTA, 200 mg/ml
PMSF, 50 mg/ml aprotinin, 5 mg/ml leupeptin, 200 mM sodium
orthovanidate) or lysed directly in the plate. The hPrEC lines were
harevested 4 days post infection, while stably infected BPH-1 cells
were collected 4 days post selection in puromycin (1 mg/ml).
Protein concentrations were determined using Bradford Protein
Assay Reagent (BIO-RAD, Hercules, CA), following manufactur-
er’s protocol. For Western blot analysis, protein extract was
subjected to gel electrophoresis either on a Tris-glycine polyacryl-
amide gel (Invitrogen) (LNCaP and mPrE) or on a Nu Page 3–8%
Tris-acetate polyacrylamide gel (Invitrogen) (BPH-1 and hPrEC).
The gel was transferred to Optitran nitrocellulose membrane
(Schleicher & Schuell Biosciences Inc. Keene, NH) by electro-
phoresis for 1 hour at 45 V. The membrane was blocked in 10%
nonfat dry milk in TBST (10 mM Tris, 250 mM NaCl, 1%
Tween 20) for 1 hour at room temperature and immunoblotted
with primary antibodies for AR (N-20, Santa Cruz, Santa Cruz,
CA), E2F1 (KH-95, Pharmingen, Franklin Lakes, NJ), Rb
(Pharmingen), PCNA (C-20, Santa Cruz), E-Cadherin (H-108
Santa Cruz), Cyclin E (M-20, Santa Cruz), DNMT1 (Raw
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BioLabs Inc., Ipswich, MA), b-actin (C-11, Santa Cruz), or actin
(AC-40 Sigma, St. Louis, MO). The membrane was incubated
with secondary antibody conjugated to horseradish peroxidase
(BIO-RAD, Hercules, CA) and the bands were detected using
ECL (PIERCE, Rockford, IL) detection system, following
manufacturer’s protocol.
Luciferase Assay
LNCaP and PrE cells were plated at 2610
5 cells per 6 well dish
and incubated at 37uC overnight. Stably infected BPH-1s with
DNMT1 shRNAs were plated at a 1 to 60 passage into a 12 well
dish and incubated at 37uC overnight. Cells were co-transfected
with 1 mg/ml of either of the following promoter-luciferase
reporter constructs; DHFR-Luc, E2F-Luc and CRE-Luc were
kindly provided by G. Denis, Boston University, Boston, MA [80],
2.0 kb human AR promoter-Luc (hAR-Luc) (kindly provided by F.
H. Sarkar, Wayne State University, Detroit, MI), 1.5 kb mouse
AR promoter-Luc (mAR-Luc) was kindly provided by D. J.
Tindall, Mayo Clinic, Rochester, MN [81], MMTV-Luc (gift from
E. Keller, University of Michigan, Ann Arbor, MI) and 3XHRE-
Luc (gift from D. Robins, University of Michigan, Ann Arbor,
MI). The promoter-reporter constructs were co-transfected in
LNCaP and PrE cells with either empty pcDNA3 vector, wild type
E2F1 or the following E2F1 mutants (E2F1–284, or Eco132) (gifts
from W.D. Cress, Moffitt Cancer Center, Tampa, FL, [30,82]), a
dominant negative E2F1 was kindly provided by W. Kaelin,
Harvard University, Boston, MA, [44] or Tag (gift from M.
Imperiale, University of Michigan, Ann Arbor MI). The pSV-
beta-galactosidase (b-gal, Promega) expression plasmid was co-
transfected into LNCAP and PrE cell lines at 0.1 mg/ml and into
hPrEC and BPH-1 cells at 1 g/ml as an internal control. DNA was
transfected using Tfx50 transfection reagent (Promega) at a ratio
of ,3:1 (Tfx50: DNA) following manufacturer’s protocol. After
72 hours of transfection, whole cell lysates were collected in lysis
buffer. Luciferase expression was determined by adding 50 ml
luciferase substrate (Promega) to 50 ml of lysate and luciferase was
monitored using a Monolight 2010 luminometer. B-gal expression
was monitored using B-gal Detection System (Tropix, Bedford,
MA) following manufacturer’s protocol using Monolight 2010
luminometer. Samples were assayed in triplicate and luciferase
activity was normalized to B-gal activity.
qRTPCR and PCR Analysis
Total RNA was extracted by scraping and collecting cells in
TRizol (Invitrogen, Carlsbad, CA) (1 ml per 60 mm dish). The
lysate was added at 1 ml to a pre-spun 2 ml heavy phase lock gel
tube (5 PRIME Inc., Gaithersburg, MD), incubated for 5 min at
room temperature, and combined with chloroform. After the
mixture was centrifuged at 12,0006g for 10 min at 4uC, the
resulting aqueous mixture above the wax plug was removed and
mixed together with 500 ml of isopropanol, and incubated for
10 min at room temperature. The mixture was centrifuged into a
pellet at 12,0006g for 10 min at 4uC and washed 1 time in 70%
ethanol. RNA was reconstituted in 35 ml of UltraPure Distilled
Water (Invitrgen/GiBCO, Carlsbad, CA) and quantitated with the
NanoDrop Spectrophotometer ND-1000 (Thermoscientific, Wil-
mington, DE), treated with DNase I (Invitrogen), then converted
to cDNA using the Thermoscript RT PCR Reaction System
(Invitrogen) according to the manufacture’s protocol. The
qRTPCR was conducted with human AR (forward: GACCA-
GATGGCTGTCATTCA and reverse: GGAGCCATCCAAA-
CTCTTGA) and human GAPDH (forward: TGCACCACCAA-
CTGCTTAGC and reverse: GGCATGGACTGTGGTCAT-
GAG) primers in a Mastercycler ep realpex
2 (eppendorf,
Hamburg, Germany) using SYBR green PCR Master Mix (Applied
Biosystems, Carlsbad, CA) to amplify the cDNA with the following
PCR conditions; denatured at 95uC for 3 min and subjected to 40
cycles (95uC 30 sec, 60uC 30 sec, and 72uC 30 sec). The primers
were used in a separate PCR and electrophoresed on a gel to verify
the presence of a single amplicon from the cDNA. Each sample
reaction in the qRTPCR was done in triplicate in a 96 well plate
format. Cycle threshold units were obtained using Mastercycler ep
realpex
2 software. Data was analyzed using the 2
2DDCT method
[83] relative to GAPDH values. PCR was conducted on cDNA
using the human AR and GAPDH primers referred to above in
combination with platinum PCR super mix (Invitrogen). Reactions
were run in an epindorf thermocycler denatured at 95uC for 3 min,
subjected to 35 cycles (95uC 30 sec, 60uC 30 sec, and 72uC 30 sec)
and processed on a 2% agarose gel.
Chromatin Immunoprecipitation qPCR Analysis
For each ChIP 1610
7 BPH-1 cells were cross-linked with 1%
formaldehyde for 10 min at room temperature on a rocking
platform. The reaction was quenched with 0.125 M glycine. Cells
were scraped and collected in cold PBS containing protease
inhibitors (200 mg/ml PMSF, 50 mg/ml aprotinin, 5 mg/ml
leupeptin, and 200 mM sodium orthovanidate), following 2 washes
in cold PBS. The harvested cells were pelleted at 5,000 rpm for
6 min at 4uC and washed once with cold PBS containing protease
inhibitors. Lysates were prepared using the reagents in the Magna
ChIP A kit (Millipore, Temecula, CA) according to manufacture
instructions, however, the lysis buffer available was substituted
with 400 ml of SDS lysis buffer (Millipore) containing kit supplied
protease inhibitors. The chromatin in the lysate was sheared to
#600 bps in a 2 ml tube placed in a Covaris S2 (Covaris Inc.,
Woburn, MA) water bath set to the following cavitation
parameters: duty cycle, 20%; intensity, 5; cycles per burst, 200;
cycle time, 30 sec; and cycles, 30. The sheared chromatin was
processed and immunoprecipitated with 5 mg of either DNMT1
(ab19505, abcam, Cambridge, MA) or rabbit IgG (sc-2027, Santa
Cruz) using the reagents and instructions provided in the Magna
ChIP A kit. The purified ChIP DNA was retrieved with 40 mlo f
elution buffer C. The DNA sample was amplified with a two step
PCR program (Denaturation at 95uC for 10 min and 40 cycles of
95uC for 15 sec and 60uC for 1 min) using SYBR green PCR
Master Mix in a StepOnePlus Real-Time PCR thermocycler
(Applied Biosystems) employing the following primers; human E2F
site A (forward: GACTCGCAAACTGTTGCATT and reverse:
TACAGCACTGGAGCGGCTA), Site B (forward: CCTAG-
CAGGGCAGATCTTGT and reverse: TCCCCTTCTCTTGC-
TCAGAA), Site C (forward: GGTAGGAAGTGGCTGAATTC-
TGGATGA and reverse: CCCTGCCCATGCACCTGCTC),
PS2 (forward: TTCCGGCCATCTCTCACTAT and reverse:
CGGGGATCCTCTGAGACA), and ABCB1 (forward: TCTA-
GAGAGGTGCAACGGAAGCCA and reverse: CCTGCCCAG-
CCAATCAGCCT). An extended program (95uC for 15 min,
60uC for 1 min, and 95uC for 15 sec) was used to create a melting
curve that was analyzed with the StepOne software v2.1 package
to verify that the primers only amplify a single amplicon from
genomic DNA. Each sample reaction in the qPCR was done in
triplicate in a 96 well plate format. Cycle threshold units were
obtained using StepOne software v2.1. Data is represented as a
percent of input using a derivation of the 2
2DCT method [83].
Bisulfite sequencing
Genomic DNA (gDNA) was extracted from cells using the
Wizard Genomic DNA Purification kit (Promega) and quantified
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tific, Wilmington, DE). A 250 ng sample of DNA was bisulfite
converted using the EZ DNA Methylation-Direct kit (Zymo
Research, Orange, CA) according to the instructions provided by
the manufacturer. The following bisulfite converted DNA specific
primers, targeting a region in the AR (NM_000044) minimal
promoter (forward: GGGAGTTAGTTTGTTGGGAG and re-
verse: TCCTACCAAACACTTTCCTTACT), were created with
Methyl Primer Express v1.0. Amplification of the bisulfite
converted gDNA was accomplished using special ZymoTaq
PreMix (Zymo Research) polymerase to facilitate the production
of amplicons with A overhangs using the following PCR program:
denature at 95uC for 10 minutes, run 35 cycles (95uC 30 sec, 59uC
30 sec, and 72uC 60 sec), run a final extension at72uC for 7 min,
and hold at 4uC. PCR product was combined with pCR8/GW/
TOPO TA cloning vector (Invitrogen) in a mixture prescribed by
the manufacture to facilitate the insertion of the amplified
products into the plasmids which contain sequencing primer sites
that flank the insert. Plasmids were transformed and plated in One
Shot Top 10 chemically competent cells (Invitrogen) per
manufacturer’s instructions and at least 12 bacterial colonies were
individually grown in 5 ml of LB containing spectinomycin
(100 mg/ml). Plasmids were harvested from the bacteria using
the Wizard Plus SV Miniprep kit (Promega) and sequenced with
the M13 forward and reverse primers at the University of
Michigan DNA sequencing core.
Statistics
Data showing significance was analyzed using 2-tailed Student’s
t test. P,0.05 was accepted as the level of significance.
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